Infigratinib not checked
QED Therapeutics, a BridgeBio company · BGJ398
FollowEvery change as it happens, and a Monday email
Trials
4 active
7 in total · 4 in the EU
What this is
- How it works
- Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-tinib: tyrosine kinase inhibitors WHO name stem
- How it’s given
- “* The dose of infigratinib will be the dose confirmed in the Phase 2 portion and used in the Phase 2b portion for the age group. * The dose and number of sprinkle capsules/day will be calculated based on individual participant age and weight. Doses will be adjusted based on age and weight changes approximately every 3 months for the first year and every 6 months thereafter.”In the company’s words, NCT07169279 on ClinicalTrials.gov
- Tested for
- Hypochondroplasia (2 trials), Achondroplasia (2 trials)
- Main trialPhase 2/3
- “ACCEL2/3 is a Phase 2/3 study. The purpose of the Phase 2 portion of the study (ACCEL2/3) is to evaluate the efficacy and safety of infigratinib in children with hypochondroplasia (HCH) receiving infigratinib at one of two doses, who have completed at least 26 weeks of participation in QED-sponsored ACCEL (QBGJ398-004).”In the company’s words, NCT06873035 on ClinicalTrials.gov
- Other names
- BGJ398
Other drugs for Hypochondroplasia
- VosoritideBioMarin Pharmaceutical · Phase 3
- NavepegritideAscendis Pharma A/S · Phase 3
Coming up4
- Jan 2027Phase 2/3 trial completes · ClinicalTrials.gov
- Mar 2030Phase 2 trial completes · ClinicalTrials.gov
- 1 Dec 2031Phase 2 trial completes · ClinicalTrials.gov
- 31 May 2036Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials7
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Enrolling by invitation | Jan 2027 | An Interventional Study of Infigratinib in Children With Hypochondroplasia | |
| Phase 2Recruiting | Mar 2030 | Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH) | |
| Phase 2Enrolling by invitation | 1 Dec 2031 | Extension Study of Infigratinib in Children With Achondroplasia (ACH) | |
| Phase 2Enrolling by invitation | 31 May 2036 | Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia | |
| Phase 3Terminated | 2 Mar 2023 | Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations | |
| Phase 2Terminated | 1 Mar 2021 | A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma | |
| Phase 2Completed | 10 Jan 2023 | LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026